Intuitive Surgical (ISRG)
(Delayed Data from NSDQ)
$507.42 USD
+1.08 (0.21%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $507.62 +0.20 (0.04%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$507.42 USD
+1.08 (0.21%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $507.62 +0.20 (0.04%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
Zacks News
Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel
by Zacks Equity Research
Zacks Market Edge Highlights: Intuitive Surgical, BioTelemetry, Edwards Lifesciences, Penumbra and Vericel
Boston Scientific Grows on Acquisitions, Product Launches
by Zacks Equity Research
Boston Scientific's (BSX) strategy to extend its existing portfolio through inorganic growth profile has been advancing well. Further, this should help aid the company's top line in the long term.
How to Invest in the Hot Medical Device Innovators
by Tracey Ryniec
Forget the biotechs. Medical device companies are innovating in amazing ways. Here's how to invest.
Abbott's CE Mark for FreeStyle Libre 2 Boosts Diabetes Arm
by Zacks Equity Research
Abbott (ABT) focuses on boosting diabetes care. The latest CE Mark will increase the top-line contributions from the Diabetes unit.
Stryker's HyperBranch Buyout to Boost Neurotechnology Business
by Zacks Equity Research
Stryker's (SYK) craniomaxillofacial division's market prospects bright.
Here's Why You Should Invest in CVS Health (CVS) Stock Now
by Zacks Equity Research
CVS Health's (CVS) solid cash position is encouraging. Strong 2019 PBM selling season is another upside.
Here's Why You Should Buy Inogen (INGN) Stock Right Now
by Zacks Equity Research
Inogen (INGN) is expected to gain from strong international foothold and a raised view for 2018.
Henry Schein's 3 Investments to Fortify Dental Implant Arm
by Zacks Equity Research
Intra-Lock, Medentis Medical and Pro-Cam Implants jointly are likely to prove conducive to growth for Henry Schein's (HSIC) existing implant-based tooth replacement solutions line.
Quest Diagnostics Plans a Buyout to Widen TB Testing Suite
by Zacks Equity Research
Quest Diagnostics (DGX) progresses well with regard to its strategy to grow inorganically.
The Zacks Analyst Blog Highlights: Alphabet, Bank of America, PepsiCo, Eli Lilly and Intuitive Surgical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alphabet, Bank of America, PepsiCo, Eli Lilly and Intuitive Surgical
STERIS (STE) Strategic Growth Strong Amid Several Headwinds
by Zacks Equity Research
STERIS (STE) impresses with favorable underlying market trends apart from new products and service offerings. Yet, a severe competition lurking beneath is worrisome for the company.
Top Research Reports for Alphabet, Bank of America & PepsiCo
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Bank of America (BAC), and PepsiCo (PEP).
Quest Diagnostics Inks Lab Service Deal With ReproSource
by Zacks Equity Research
Per agreement with ReproSource, Quest Diagnostics (DGX) to perform laboratory reference testing besides providing supply chain expertise.
Abbott's Troponin-I Wins CE Mark, Vascular Arm Gets a Revamp
by Zacks Equity Research
Abbott's (ABT) life-changing High Sensitive Troponin-I test uses a biomarker, specific to the heart.
Hologic's Focal Therapeutics Buyout to Boost Breast Health Arm
by Zacks Equity Research
Hologic (HOLX) progresses with initiatives to boost the Breast Health unit. The recent buyout is likely to widen portfolio and fortify Hologic's position in the breast conserving surgery market.
Here's Why You Should Add Edwards Lifesciences Right Away
by Zacks Equity Research
We are upbeat about the continued strength in Edwards Lifesciences' (EW) THVT business.
Will LabCorp's (LH) Food Solution Divestment Upset Sales?
by Zacks Equity Research
LabCorp's (LH) lackluster outlook for 2018 includes the earlier-announced divestment of its Food Solutions business.
Neogen (NEOG) Earnings Beat, Revenues Lag Estimates in Q1
by Zacks Equity Research
Accretive integrations and an expanding international footprint drive Neogen's (NEOG) earnings in Q1.
Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ISRG) Outperforming Other Medical Stocks This Year?
Here's Why You Should Invest in Walgreens Boots Stock Now
by Zacks Equity Research
Walgreens Boots (WBA) gains from tie-ups. The company's alliance with Express Scripts encourages.
Boston Scientific's FDA Nod for Eluvia Stent Expands PI Suite
by Zacks Equity Research
Boston Scientific's (BSX) PMA approval for Eluvia Drug-Eluting Vascular Stent System will help boost the top line at the PI business.
Intuitive Surgical and InTouch Collaborate for IoMT Services
by Zacks Equity Research
Intuitive Surgical's (ISRG) IoMT likely to benefit patients; market prospects impressive.
Here's Why You Should Buy Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Strength in the surgical platform and a string of developments make Intuitive Surgical (ISRG) a promising pick.
Medtronic to Buy Mazor Robotics for Robotic Spine Surgery
by Zacks Equity Research
The consolidation will combine Medtronic's (MDT) spine implants, navigation and intra-operative imaging technology with Mazor Robotics' robotic-assisted surgery (RAS) systems.
3 MedTech Stocks for Safe Returns as Hurricane Fears Peak
by Sweta Jaiswal
With the hurricane season at the peak, we bring three safe picks for investors.